DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Blair William & Co. IL

Blair William & Co. IL reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,232,647 shares of the medical device company’s stock after selling 509,462 shares during the period. Blair William & Co. IL’s holdings in DexCom were worth $173,633,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. NEOS Investment Management LLC lifted its stake in shares of DexCom by 15.3% in the 4th quarter. NEOS Investment Management LLC now owns 76,172 shares of the medical device company’s stock worth $5,924,000 after acquiring an additional 10,113 shares during the period. Sava Infond d.o.o. acquired a new stake in shares of DexCom in the fourth quarter worth $474,000. Elo Mutual Pension Insurance Co grew its stake in DexCom by 14.1% in the fourth quarter. Elo Mutual Pension Insurance Co now owns 40,159 shares of the medical device company’s stock valued at $3,123,000 after purchasing an additional 4,968 shares in the last quarter. WINTON GROUP Ltd bought a new stake in DexCom in the fourth quarter worth approximately $3,259,000. Finally, Artisan Partners Limited Partnership boosted its stake in shares of DexCom by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company’s stock worth $144,152,000 after acquiring an additional 201,181 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Canaccord Genuity Group raised their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Stock Performance

NASDAQ:DXCM opened at $72.13 on Thursday. The stock has a 50 day simple moving average of $82.96 and a 200 day simple moving average of $77.07. The stock has a market cap of $28.19 billion, a P/E ratio of 50.44, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $141.99. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.